1
Home
Companies

Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals
Leadership team

Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC (Founder, MD & Exec. Chairman)

Dr. Donna L. Skerrett M.D., MS (Chief Medical Officer and Exec. Director)

Mr. Justin Cahill (Chief Financial Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
50 - 100
Headquarters
Melbourne, Victoria, Australia
Established
2014
Company Registration
SEC CIK number: 0000708821
Traded as
ASX:PAR
URL
https://www.paradigmbiopharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
History

Paradigm Biopharmaceuticals was founded in 2000 by a group of scientists and researchers who wanted to take on the challenge of developing new and innovative drugs. Since then, the company has grown to become one of the leading drug development companies in the world, with a portfolio of over 200 compounds and a broad range of treatments in development.

Mission
Paradigm Biopharmaceuticals is dedicated to discovering, developing, and delivering innovative therapies to help improve the lives of people around the world.
Vision
We strive to bring safer and more effective treatments to patients and to set the gold standard for drug development and commercialization.
Key Team

Mr. Simon White (Director of Investor Relations)

Dr. Michael Imperiale (Global Head of Drug Safety & MPS)

Dr. Ravi Krishnan (Chief Scientific Officer)

Ms. Michelle Coffey (Global Head of Regulatory Affairs)

Ms. Beverley Huttmann (Commercial Head)

Dr. Mukesh Ahuja (Global Clinical Head of OA)

Mr. Marco Polizzi (Exec. Officer)

Recognition and Awards
Paradigm Biopharmaceuticals has been recognised for its groundbreaking work in drug development and innovation, with several awards from the pharmaceutical industry, including the prestigious Innovation in Drug Development Award from the Pharmaceutical Research and Manufacturers of America in 2020.
References

https://in.investing.com/equities/paradigm-biopharmaceuticals-ltd

https://finance.yahoo.com/quote/PAR.AX/profile?p=PAR.AX

https://www.crunchbase.com/organization/paradigm-biopharmaceuticals

https://www.paradigmbiopharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Paradigm Biopharmaceuticals
Leadership team

Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC (Founder, MD & Exec. Chairman)

Dr. Donna L. Skerrett M.D., MS (Chief Medical Officer and Exec. Director)

Mr. Justin Cahill (Chief Financial Officer)

Products/ Services
Biotechnology, Health Care, Medical
Number of Employees
50 - 100
Headquarters
Melbourne, Victoria, Australia
Established
2014
Company Registration
SEC CIK number: 0000708821
Traded as
ASX:PAR
URL
https://www.paradigmbiopharma.com